Want to see NATR full AI Analyst Report?
Top Page
Nature's Sunshine Products
(NASDAQ:NATR)
Select Model
Select Model
Rating:57Neutral
Price Target:
$21.00
▲(2.94% Upside)
Action:Reiterated
Date:08/07/26
The score is held back primarily by weakened cash-flow conversion (despite revenue growth and strong gross margins) and bearish technical momentum. A conservative balance sheet and constructive digital/margin progress from the earnings call provide support, while valuation appears reasonable but not compelling without a dividend yield.
Positive Factors
High gross margins
Sustained ~73% gross margins reflect durable advantages in manufacturing, sourcing and pricing discipline. High gross margin capacity provides structural protection for profitability as revenue scales, enabling investment in digital growth and higher operating leverage even if SG&A rises.
Negative Factors
Weak cash conversion / FCF decline
A ~40% drop in FCF and operating cash flow that lags net income signals working capital or reinvestment strains. Persistent weak cash conversion can limit ability to self‑fund growth initiatives, increase reliance on external financing, and constrain shareholder returns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained ~73% gross margins reflect durable advantages in manufacturing, sourcing and pricing discipline. High gross margin capacity provides structural protection for profitability as revenue scales, enabling investment in digital growth and higher operating leverage even if SG&A rises.
Read all positive factors
Nature's Sunshine Products (NATR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$354.34M
Dividend YieldN/A
Average Volume (3M)115.94K
Price to Earnings (P/E)18.2
Beta (1Y)0.63
Revenue Growth7.26%
EPS Growth104.70%
CountryUS
Employees806
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)1.02
Shares Outstanding17,584,871
10 Day Avg. Volume93,059
30 Day Avg. Volume115,935
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.41
Price to Sales (P/S)0.81
P/FCF Ratio13.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$34.50Price Target Upside69.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.18
Revenue Forecast (FY)$507.70M
Nature's Sunshine Products Business Overview & Revenue Model
Company Description
Nature's Sunshine Products, Inc. is a natural health and wellness enterprise that primarily manufactures and distributes a wide array of nutritional supplements and personal care products. The company's operational reach spans several continents, ...
How the Company Makes Money
Nature’s Sunshine makes money primarily by selling its branded nutritional supplements and personal care products. The core revenue stream is product sales: (1) Direct selling/affiliate channel: the company sells products to end customers through ...
Nature's Sunshine Products Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but constructive picture: the company delivered record Q2 sales, strong digital momentum, notable margin expansion and maintained a clean balance sheet and zero debt, while also announcing experienced senior hires and an ambitious 'Vision for Growth.' Offsetting these positives were a material decline in China, lower full‑year guidance (sales and EBITDA), a shift to negative operating cash flow in the quarter, continued pressure in the core direct selling business in North America, and near‑term SG&A increases to fund growth initiatives. Management framed key negatives (China, FX) as addressable and emphasized strategic investments to accelerate long‑term growth.Positive Updates
Record Second Quarter Net Sales
Net sales of $117.0M in Q2, the strongest second quarter in company history; +2% year-over-year (or +4% excluding foreign exchange).
Negative Updates
Significant China Sales Decline
China sales down 20% YoY, a reversal from recent >30% growth, attributed to operational issues; management expects issues to be short term but the decline materially impacted APAC results.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Second Quarter Net Sales
Net sales of $117.0M in Q2, the strongest second quarter in company history; +2% year-over-year (or +4% excluding foreign exchange).
Read all positive updates
Company Guidance
Management lowered full-year net sales guidance to $490–$500 million (down from $500–$515 million) and cut full-year EBITDA guidance to $48–$52 million (from $50–$54 million); they expect gross margin to average in the low‑ to mid‑73% range for the remainder of 2026 and quarterly SG&A to run about $45–$47 million, while Q2 reported net sales were $117 million with adjusted EBITDA of $11.3 million, digital sales on track for about $50 million by year‑end (digital +26% in Q2, new customers +26%, autoship = 36% of web orders, social commerce +177% with 60% autoship), volume incentives at 30.6% of sales, cash and equivalents of $82.5 million with zero debt, net cash used by operations of $1.1 million (vs. $6.9 million provided prior year), and 113,000 shares repurchased for ~$2.5 million leaving $14.8 million remaining in the buyback program.Nature's Sunshine Products Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
82
Very Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 492.02M | 480.14M | 454.36M | 445.32M | 421.91M | 444.08M |
| Gross Profit | 359.98M | 347.72M | 324.69M | 321.13M | 299.76M | 328.62M |
| EBITDA | 42.16M | 43.75M | 32.79M | 32.09M | 31.15M | 43.23M |
| Net Income | 18.10M | 19.52M | 7.70M | 15.08M | -390.00K | 28.85M |
Balance Sheet | ||||||
| Total Assets | 259.82M | 261.15M | 240.85M | 249.77M | 229.78M | 258.87M |
| Cash, Cash Equivalents and Short-Term Investments | 82.50M | 93.89M | 84.70M | 82.37M | 60.03M | 86.18M |
| Total Debt | 21.43M | 18.90M | 14.20M | 14.92M | 19.18M | 22.99M |
| Total Liabilities | 90.51M | 99.59M | 79.86M | 90.23M | 82.73M | 97.47M |
| Stockholders Equity | 169.32M | 161.55M | 155.31M | 154.06M | 142.91M | 158.20M |
Cash Flow | ||||||
| Free Cash Flow | 13.76M | 28.84M | 14.33M | 30.75M | -6.92M | 27.94M |
| Operating Cash Flow | 25.52M | 35.32M | 25.30M | 41.23M | 710.00K | 34.61M |
| Investing Cash Flow | -17.92M | -6.48M | -10.97M | -10.48M | -7.63M | -6.61M |
| Financing Cash Flow | -11.37M | -23.77M | -9.90M | -7.96M | -16.25M | -31.72M |
Nature's Sunshine Products Technical Analysis
Negative
20.40
Price Trends
20.65
Negative
22.68
Negative
22.41
Negative
Market Momentum
-0.53
Positive
24.45
Positive
21.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NATR, the sentiment is Negative. The current price of 20.4 is below the 20-day moving average (MA) of 20.46, below the 50-day MA of 20.65, and below the 200-day MA of 22.41, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 24.45 is Positive, neither overbought nor oversold. The STOCH value of 21.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NATR.
Nature's Sunshine Products Risk Analysis
Nature's Sunshine Products disclosed 25 risk factors in its most recent earnings report. Nature's Sunshine Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nature's Sunshine Products Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $1.29B | 5.33 | -43.03% | ― | 3.69% | -16.34% | |
60 Neutral | $81.12M | 13.92 | 17.78% | 2.90% | -12.15% | -38.04% | |
57 Neutral | $354.34M | 18.15 | 12.30% | ― | 7.26% | 104.70% | |
49 Neutral | $408.22M | 46.74 | -4.15% | ― | 5.67% | -73.96% | |
44 Neutral | $14.37M | -0.97 | -21.48% | ― | 12.37% | -69.61% |
* Consumer Defensive Sector Average
NATR
Nature's Sunshine Products
16.38
0.28
1.74%
HLF
Herbalife
12.35
3.44
38.61%
NAII
Natural Alternatives International
2.37
-1.33
-35.97%
USNA
USANA Health
15.47
-13.85
-47.24%
LFVN
LifeVantage
6.76
-6.64
-49.56%
Nature's Sunshine Products Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial Disclosures
Nature’s Sunshine Names Ruth Perkins as New CFO
Neutral
Aug 6, 2026
On August 4, 2026, Nature’s Sunshine’s board appointed Ruth Perkins as Executive Vice President and Chief Financial Officer, effective September 1, 2026, while Jon Lanoy remains Principal Accounting Officer. Perkins, a veteran of Est&#...
Executive/Board Changes
Nature’s Sunshine Appoints Interim Principal Financial Officer
Neutral
May 11, 2026
On May 8, 2026, Nature’s Sunshine Products’ Chief Financial Officer and Principal Financial Officer, L. Shane Jones, notified the company that he would resign effective June 5, 2026, with the company stating that his departure did not ...
Business Operations and StrategyShareholder Meetings
Nature’s Sunshine Shareholders Approve 2026 Stock Incentive Plan
Positive
May 8, 2026
At its Annual Meeting of Shareholders on May 6, 2026, Nature’s Sunshine Products, Inc. secured shareholder approval for its 2026 Stock Incentive Plan, authorizing up to 1,500,000 shares of common stock for equity-based awards to employees, d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.